Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by georgesoreloseon Jun 15, 2017 12:15am
173 Views
Post# 26364674

Some more takeaways from Today's Vicenza prezzie

Some more takeaways from Today's Vicenza prezzieI was impressed by today's presentation as more data was offered, along with some excellent postives from the replication of the Euphas phase II study ( terminated at patient 64 of 128 due to extreme efficacy ).  Multiple times Prof..Antonelli mentioned the most successful Euphas study and noted the Euphrates had performed in similar fashion.  One piece of new data today reflects a most impressive 15% absolute efficacy on a subgroup of 154 patients ( I have asked a nurse to explain to me - will report back ).  I was also impressed with an additional bit of information offered on the global frequency of the "non-culturable bacteria" group.  The professor showed that in cases of Septic Shock, where no bacteria were present, we achieved a 21% absolute benefit.  He later added that this group represents a "minimum of 30%" of Septic Shock cases.  I will ask MM to complete this canvas, as I am not aware of the global opportunity $ to price the 30% market.  I was assuming that 30% of this market would still be very substantial.  

The "safety thing" was kind of comforting too.  With us treating over 150,000 patients, and having 7500+ patients run in clinical studies, along with 150+ published papers, you do run the very real risk of a "safety issue" ( throat clear ).  Seems we're pretty safe, like "stupid safe".  Shirley we've all heard commercials for a very wide range of approved drugs.  The list of side effects is endless.   Now take a look at our diagnostic guided, theranostic, state-of-the-art treatment, that would seem as safe as aspirin.

 I've always admired world class swimmers because they usually seemed to peak right before the olympics or worlds.  The science is building here folks, and I feel like PMX can still be fine tuned so it makes the podium for efficacy.  The diagnostic is key, try building a shed without a tape measure.  I always remember Square saying, "the EAA is the Lufkin of endotoxin measurement".  Let's see if our diagnostic can continue to shave small, but meaningful % points off very findable subgroups of Septic Shock patients.


More thoughts on Italy domani
Jorge
Bullboard Posts